Distortion product otoacoustic emission for the screening of cochlear damage in children treated with cisplatin
✍ Scribed by Khaled Al-Noury
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 131 KB
- Volume
- 121
- Category
- Article
- ISSN
- 0023-852X
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Objectives/Hypothesis:
To detect subtle hearing changes by measuring otoacoustic emissions in patients treated with a first dose of cisplatin.
Study Design:
Prospective study.
Methods:
We recruited 26 patients (mean age at treatment, 11.3 years) into this prospective study conducted at a tertiary academic referral center. Audiograms and transient‐evoked otoacoustic emissions (TEOAEs) and distortion‐product otoacoustic emissions (DPOAEs) were measured before and after the first dose of cisplatin.
Results:
Baseline readings were compared with those recorded after the administration of the first dose of cisplatin. Two patients showed a loss of TEOAEs at high frequencies above 4 kHz, and this was consistent with the 25‐dB hearing loss of the high frequencies detected in their audiograms; there was a significant threshold shift for DPOAEs at a frequency >3 to 4 kHz (P <.05).
Conclusions:
DPOAE testing appears to be a more sensitive method to detect cochlear damage than conventional pure‐tone audiometry. Our results suggest that the measurement of DPOAE thresholds is a useful approach to detect the early auditory changes induced by cisplatin therapy.